Market Product Forecasts for currently marketed targeted cancer therapies including; an overview of sales in each of the seven major pharmaceutical markets and sales forecasts for each brand over the forecast period 2011-21.
Description
INTRODUCTION
The targeted therapies class has fueled most of the recent rapid growth of the oncology market as a whole. In the next decade the market will become more fragmented as new targeted therapies are developed for niche populations. In addition to this, recent pricing restrictions in the Eurozone will impact sales growth of targeted cancer therapies in the five major EU markets.
FEATURES AND BENEFITS
Analysis of sales forecasts of 28 targeted cancer therapy brands over the period 2011-21 in the seven major pharmaceutical markets.
Includes an overview of the overall targeted therapies market as well as country specific and brand specific forecasts.
Analysis of the impact of generics and biosimilars on the marketed targeted cancer therapy brands over the forecast period 2011-21
Analysis of pharmacoeconomic constraints likely to affect sales growth in the seven major pharmaceutical markets.
HIGHLIGHTS
Datamonitor forecasts the currently marketed targeted cancer therapies to achieve collective sales of $37.2bn by 2014 in the seven major markets (the US, Japan, France, Germany, Italy, Spain, and the UK), growing at a compound annual growth rate (CAGR) of 7.36% from 2011 to 2014.
In 2011 the MAbs achieved sales of $16.3bn accounting for 54% of the sales of currently marketed targeted cancer therapies. The impact of generic competition on small molecule brands is expected to be greater than the impact of biosimilar competition on MAbs.
The US has the largest patient population and will remain the largest market over the forecast period of 2011-21. The aggressive uptake of generics in the US market, means the L1X4, L1X9, and L4A0 classes are expected to see a significantly higher decrease in branded sales over the forecast period compared to the MAbs.
YOUR KEY QUESTIONS ANSWERED
Access Datamonitor's company-reported sales based market forecasts for 28 targeted cancer therapies in the US, Japan and the five major EU markets.
Analyze the sales forecasts in each of the seven major markets and for each of the targeted cancer therapy brands across the forecast period 2011-21.
Report is accompanied by a PowerPoint presentation and Excel deliverable showing the transparent methodology and forecasting assumptions.
Table of Contents
Table of Contents
OVERVIEW
Catalyst
Summary
EXECUTIVE SUMMARY
Strategic scoping and focus
Datamonitor key findings
Related reports
MARKET DEFINITION
Market definition for the targeted cancer therapies class
Targeted cancer therapies by ATC class
Targeted cancer therapies not included in this report
Figure: Unevented and evented company-reported sales-based forecast, 2012
Figure: Targeted cancer therapies market forecast in the seven major markets, by region ($m), 2011-21
Figure: Sales of targeted cancer therapies in the seven major markets, by class ($m), 2011-21
Figure: Sales of targeted cancer therapies in the US, by class ($m), 2011-21
Figure: Sales of targeted cancer therapies in Japan, by class ($m), 2011-21
Figure: Sales of targeted cancer therapies in the five major EU markets, by class ($m), 2011-21
Figure: Sales of targeted cancer therapies in France, by class ($m), 2011-21
Figure: Sales of targeted cancer therapies in Germany, by class ($m), 2011-21
Figure: Sales of targeted cancer therapies in Italy, by class ($m), 2011-21
Figure: Sales of targeted cancer therapies in Spain, by class ($m), 2011-21
Figure: Sales of targeted cancer therapies in the UK, by class ($m), 2011-21
Figure: Adcetris (brentuximab vedotin; Seattle Genetics/Takeda) sales, by country ($m), 2011-21
Figure: Afinitor (everolimus; Novartis) sales, by country ($m), 2011-21
Figure: Arzerra (ofatumumab; Genmab/GlaxoSmithKline) sales, by country ($m), 2011-21
Figure: Avastin (bevacizumab; Roche/Chugai) sales, by country ($m), 2011-21
Figure: Caprelsa (vandetanib; AstraZeneca) sales, by country ($m), 2011-21
Figure: Erbitux (cetuximab; Eli Lilly/Bristol-Myers Squibb/Merck KGaA) sales, by country ($m), 2011-21
Figure: Erivedge (vismodegib; Roche) sales, by country ($m), 2011-21
Figure: Gleevec (imatinib; Novartis) sales, by country ($m), 2011-21
Figure: Herceptin (trastuzumab; Roche/Chugai) sales, by country ($m), 2011-21
Figure: Inlyta (axitinib; Pfizer) sales, by country ($m), 2011-21
Figure: Iressa (gefitinib; AstraZeneca) sales, by country ($m), 2011-21
Figure: Nexavar (sorafenib; Bayer Schering/Onyx) sales, by country ($m), 2011-21
Figure: Perjeta (pertuzumab; Roche) sales, by country ($m), 2011-21
Figure: Revlimid (lenalidomide; Celgene) sales, by country ($m), 2011-21
Figure: Rituxan (rituximab; Biogen Idec/Roche/Chugai/Zenyaku) sales, by country ($m), 2011-21
Figure: Sprycel (dasatinib; Bristol-Myers Squibb) sales, by country ($m), 2011-21
Figure: Sutent (sunitinib; Pfizer) sales, by country ($m), 2011-21
Figure: Tarceva (erlotinib; OSI Pharmaceuticals/Roche) sales, by country ($m), 2011-21
Figure: Tasigna (nilotinib; Novartis) sales, by country ($m), 2011-21
Figure: Thalomid (thalidomide; Celgene) sales, by country ($m), 2011-21
Figure: Torisel (temsirolimus; Pfizer) sales, by country ($m), 2011-21
Figure: Tykerb (lapatinib; GlaxoSmithKline) sales, by country ($m), 2011-21
Figure: Vectibix (panitumumab; Amgen) sales, by country ($m), 2011-21
Figure: Velcade (bortezomib; Takeda/Johnson & Johnson) sales, by country ($m), 2011-21
Figure: Votrient (pazopanib; GlaxoSmithKline) sales, by country ($m), 2011-21
Figure: Xalkori (crizotinib; Pfizer) sales, by country ($m), 2011-21
Figure: Yervoy (ipilimumab; Bristol-Myers Squibb) sales, by country ($m), 2011-21
Figure: Zelboraf (vemurafenib; Roche/Daiichi Sankyo) sales, by country ($m), 2011-21
Market and Product Forecasts: Targeted Cancer Therapies 2011-21 - Eurozone price cuts impact targeted cancer therapies market published by Datamonitor in July 20, 2012. This report consists of Pages: 88 and the price starts from US $ 11400.
